Breaking News

WuXi PharmaTech Tox Facility Passes Belgium Inspection

May 21, 2014

Suzhou site successfully passes three GLP inspections

WuXi PharmaTech’s toxicology facility in Suzhou has received a statement of Good Laboratory Practice (GLP) from the Belgium Scientific Institute of Public Health on behalf of the Organization for Economic Cooperation and Development (OECD). The facility passed three GLP inspections covering organizational processes and conditions under which health safety studies are planned, performed, monitored, recorded, archived, and reported.
 
The inspection audited 22 studies in areas that included general toxicology, genetic toxicology, safety pharmacology, dermal irritation, skin phototoxicity, and immunology.  
 
"The Belgian GLP statement for our toxicology facility is a further acknowledgment of the quality of our services, which meet the highest international standards," said Dr. Ge Li, chairman and chief executive officer of WuXi PharmaTech. "With this recognition, WuXi has further solidified its leadership in offering the highest-quality toxicology service in China. Toxicology is an important part of WuXi's comprehensive, fully integrated platform of services for our global and domestic pharmaceutical and biotech clients."

Related Compliance:

blog comments powered by Disqus
  • CMO Systems

    CMO Systems

    Philip K. Burns, CRO Consulting||April 5, 2016
    A CMO system includes four aspects of the product lifecycle: regulatory, technical, compliance, and operations.

  • Injectables: The New Oral?

    Injectables: The New Oral?

    Tugrul Kararli, Kurt Sedo, Josef Bossart, PharmaCircle LLC||April 5, 2016
    The growth trend of injectables continues across the pharma landscape.

  • Biopharmaceutical Contract Manufacturing Contract Negotiations

    Biopharmaceutical Contract Manufacturing Contract Negotiations

    William Downey, HighTech Business Decisions||April 5, 2016
    Navigating the complexities of supply agreements.